Navigation Links
Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older
Date:12/22/2010

ve disease) caused by the Streptococcus pneumoniae (S. pneumoniae) serotypes in the vaccine. In the European Union, the Company is seeking marketing authorization for active immunization for the prevention of disease caused by S. pneumoniae in adults aged 50 years and older. Pfizer plans regulatory submissions in additional countries in 2011.

Pfizer's applications to the FDA and EMA are based on six Phase III studies involving approximately 6,000 subjects. Data from the studies are expected to be shared in peer-reviewed forums beginning in 2011.

Pneumococcal Disease

Pneumococcal disease is a group of illnesses caused by the bacterium S. pneumoniae, also known as pneumococcus. It includes invasive infections such as bacteremia, sepsis, and meningitis, as well as non-invasive infections, such as pneumonia and otitis media. Pneumococcal disease is a major cause of illness and death in adults worldwide.

Indication for Prevnar 13 for Pediatric Use in the United States

In the United States, Prevnar 13 is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the sixth birthday). Prevnar 13 is indicated for active immunization for the prevention of invasive disease caused by 13 serotypes of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13 is also indicated for the prevention of otitis media (ear infection) caused by seven serotypes of S. pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F). No efficacy data for ear infections are available for serotypes 1, 3, 5, 6A, 7F, and 19A.

Prevnar 13 is not indicated for the prevention of pneumonia in the United States.

Important Safety Information for Prevnar 13 for Pediatric Use in the United States

Prevnar 13 should not be given to anyone with a severe allergic reaction to any component of Prevnar 13, Prevnar, or any diphtheri
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
2. Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman
3. Pfizer Declares A 20-Cent First-Quarter 2011 Dividend
4. Young Children In Developing World Receive Accelerated Access to Pfizers Prevenar 13 Vaccine
5. Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer
6. Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
7. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
8. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
9. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
10. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
11. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Valeritas, Inc., a medical technology ... innovative drug delivery solutions, announced today that the ... company,s V-Go Disposable Insulin Delivery Device for use ... delivery of insulin in preset basal rates and ...
... Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... in the development, assembly, marketing and sale of ... today announced that management will present at the ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) Rodman & ...
Cached Medicine Technology:Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 3Dehaier Medical Announces March Investor Presentations 2
(Date:7/12/2014)... July 12, 2014 The report, "Phthalic ... Resins) Market by Application & Geography – Trends & ... with analysis and forecasting of market volume and value. ... the derivatives separately. The market of phthalic anhydride is ... 2013 to $8,415.89 million by 2018, with a CAGR ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The fastest-growing ... for test and measurement of LTE networks continues to ... demands for smart devices have increased mobile data traffic, ... and Measurement (CT&M) market. Communications Test and Measurement equipment ... requirements. , The Communications Test and Measurement Market is ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit Body Boot Camp, ... also known for his support of local non-profits like the Boys ... two and is excited to announce that his fitness boot ... , The funds are the result of Francis’ 21-Day Tummy Tuck ... emails and asked his clients to put out the word that ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... 10 Enstar Group,Limited ("Enstar") (Nasdaq: ... Enstar Australia Holdings Pty Limited, had entered ... AMP Limited ("AMP") of AMP,s,Australian-based closed reinsurance ... of AUS$585 million (approximately US$518 million)., ...
... it may cause the effect through cerebrovascular disease , ... may be associated with increased risk for mild cognitive ... University Medical Center in New York City. , Mild ... "attracted increasing interest during the past years, particularly as ...
... People rate their smiles higher than dentists do, according ... most important features of an attractive face, the study also ... with their smiles., The study, published in this months Journal ... Norway to rate their own smiles on a 100-point satisfaction ...
... Scheduled for 4:00 p.m. Eastern Time to Review Clinical, Trial ... ... the ASH Meeting, ATLANTA, Dec. 10 ... developing,novel anticancer therapeutics, presented positive results for SNS-595 in,relapsed or refractory ...
... of MGCD0103 Determined as 90 mg, * 53% of Patients ... Responses Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ... (TSX: MYG) today announced maturing data,from the Phase 1/2 study investigating the ...
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
Cached Medicine News:Health News:Enstar Group Limited Announces Acquisition 2Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 3Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 4Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 5Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:2007 Human Research Protection Award Recipients Announced 2
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... technology that makes fully integrated communication ... a reality. This advance in communication, ... levels means a significantly improved ... stays and improved outcomes. And its ...
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff....
Medicine Products: